Twitxy Saved

AlamarBio

Verified account This account is verified. Learn more

@AlamarBio

Joined May 2022
9 Following 186 Followers 315 Posts

Latest posts 5

AlamarBio Verified account @AlamarBio
NULISA data featured in 46 presentations at #CTAD2026: 10 oral presentations and 36 posters from more than 30 academic, clinical, and biopharma groups across 10 countries.

The research covers brain-derived and CNS-selective p-tau217, biomarker readouts from interventional trials including Auτonomy, FINGER, and APOLLOE4, plasma proteomic responses to lecanemab and ARIA, synaptic and inflammatory signatures, and conditions beyond Alzheimer’s disease such as CTE, TDP-43 pathology, and primary tauopathies.

Download the full listing here: na2.hubs.ly/H08_XfP0

Talks run Nov 16 to 19 in the Ballroom (4th floor). Posters are across Sessions 1 to 3 in the Atrium and Gloucester rooms (3rd floor). Please stop by and talk with the presenters about their work!

Alamar colleagues will be onsite and welcome discussion about your Alzheimer's research needs.
AlamarBio Verified account @AlamarBio
@EmoryUniversity research utilizing Alamar Biosciences’ NULISA™ technology was recently featured in @FierceBiotech, highlighting advances in blood-based biomarker discovery for amyotrophic lateral sclerosis (ALS).

Led by Eleanor Thomas, MD, PhD, the study, published in @Nature Communications, identified a 10-protein biomarker signature that distinguished ALS patients from healthy controls with 98.3% accuracy in an independent validation cohort.

By combining ultrasensitive proteomics with machine learning, the findings demonstrate the potential of multi-protein biomarker signatures to distinguish ALS patients from healthy controls with high accuracy, underscoring the value of NULISA™ technology in advancing biomarker discovery for neurodegenerative diseases.

🔗 Read the Fierce Biotech coverage: fiercebiotech.com/research/resea…

#FierceBiotech #NULISA #ALS #Proteomics #Biomarkers
www.fiercebiotech.com ‘They’ve been misdiagnosed for too long’: Researchers use 10-protein panel to improve ALS detection By the time a neurodegenerative condition has been diagnosed, the disease may already be causing irreversible damage. | By the time a neurodegenerative condition has been diagnosed, it's often too...
AlamarBio Verified account @AlamarBio
Can proteomics help measure biological aging and reveal whether interventions are making a difference?
 
From biological aging clocks to clinical trials and population cohorts, proteomics is opening new possibilities in geroscience.
 
In our upcoming webinar with GEN, Dr. Michael Corley (UC San Diego), Prof. Claire Steves (King's College London), and Dr. Xiao-Jun Ma (Alamar Biosciences) will explore how ultra-sensitive, multiplexed proteomics is advancing aging research.
 
Hear how proteomic aging clocks can predict age-related health outcomes, how clinical trial data can reveal the effects of interventions, and how longitudinal proteomics can uncover new insights into aging, resilience, and disease risk.
 
💡 Stay for a live Q&A with both speakers
🔗 Register now: na2.hubs.ly/H08Z1gZ0
 
#NULISA #Proteomics #Geroscience #AgingResearch #Biomarkers #Webinar
AlamarBio Verified account @AlamarBio
Discover what’s possible when immune profiling goes beyond individual cytokines.
 
Join Caroline Chan, PhD (Alamar Biosciences) and Katharina Stracke, PhD (GeneWorks) for an upcoming webinar exploring how the NULISAseq™ Immune 340 Panel is advancing immune profiling and opening new opportunities for biomarker discovery and treatment-response research across autoimmunity and cancer immunology.
 
📍ANZ researchers: stay to the end to learn how to apply for the Immune 340 Pilot Program.
Register now: na2.hubs.ly/H08SrR70
 
#NULISA #Proteomics #Immunology #Autoimmunity #ImmunoOncology
AlamarBio Verified account @AlamarBio
Our hybrid seminar with the IRCCS Regina Elena National Cancer Institute is just one day away!

Join us tomorrow as leading researchers and experts discuss how NULISA™ Technology is being applied to biomarker research across oncology, immuno-oncology, inflammation, and neuroinflammation.

Register today to attend in person or virtually: na2.hubs.ly/H08NWCT0

#NULISA #Proteomics #Oncology #ImmunoOncology #Biomarkers